Evolus (EOLS) Expected to Announce Earnings on Tuesday

Evolus (NASDAQ:EOLS) is projected to issue its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect the company to announce earnings of $0.09 per share and revenue of $89.5810 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Evolus Trading Down 0.9%

EOLS stock opened at $4.33 on Tuesday. The company has a market capitalization of $280.67 million, a PE ratio of -4.71 and a beta of 1.12. The business’s fifty day moving average price is $5.44 and its 200 day moving average price is $6.32. Evolus has a 12-month low of $4.09 and a 12-month high of $14.94.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total transaction of $75,353.85. Following the completion of the sale, the insider owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Meeder Asset Management Inc. acquired a new position in Evolus in the fourth quarter worth $34,000. Wexford Capital LP acquired a new stake in shares of Evolus in the third quarter valued at approximately $37,000. Aquatic Capital Management LLC bought a new position in Evolus in the 3rd quarter worth approximately $48,000. State of Wyoming acquired a new stake in shares of Evolus in the 4th quarter worth approximately $63,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Evolus by 340.2% in the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after acquiring an additional 5,691 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Wall Street Analysts Forecast Growth

EOLS has been the subject of a number of analyst reports. HC Wainwright lowered their target price on shares of Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. BTIG Research reduced their price objective on Evolus from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Evolus has an average rating of “Moderate Buy” and an average target price of $17.50.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.